OTCPK:WLDCF - Post by User
Post by
Kevelleon Jan 07, 2018 9:43pm
126 Views
Post# 27302780
ICC Labs Inc. Announces Increase of Expected Processing
ICC Labs Inc. Announces Increase of Expected Processing ICC Labs Inc. Announces Increase of Expected Processing Capacity at Extraction Laboratory to Up to 150,000 kg of Dried Cannabis sativa L. Flowers Per Year
Highlights: - ICC Labs Inc. will increase prospective cannabinoid extract production capacity over 200%. - ICC Labs Inc. will increase prospective pure cannabidiol ("CBD") crystal production over 700%, among other cannabinoids.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 5, 2018) - ICC Labs Inc. ("ICC Labs" or the "Company") (TSX VENTURE:ICC), a fully licensed producer and distributor of medicinal cannabinoid extracts, recreational cannabis and industrial hemp products in Uruguay is pleased to announce the increase of the expected production capacity of its cannabinoid extraction laboratory currently being constructed. The expansion will position the Company as a global supplier of medicinal products, as well active pharmaceutical ingredients (APIs) for the pharmaceutical industry.
ICC Labs will increase the proposed production capacity at its state of the art laboratory being constructed in Uruguay from 50,000 kg per year of dry cannabinoid flowers to 150,000 kg per year by purchasing a second line supercritical fluid CO2 extractor. The Company intends to produce up to 8 million 30-millilitre bottles of its branded cannabinoid oil, 'BIDIOL' with various concentrations and 3,000 kgs of pure CBD crystals upon completion of its laboratory. The laboratory is expected to be fully operational by the second quarter of 2018 and to be GMP compliant.
"Our dynamic processing facility will give us the versatility which to get access to and supply various countries with high quality cannabinoid oils and crystals, including in South America where we hold an early mover advantage.
"We are also innovating in the use of a new technology that will allow us to increase our expected production capacity of pure CBD crystals over 700%, and will also allow us to isolate the specific cannabinoids so as to enable us to formulate various pharmaceutical and medicinal products.
"We expect our line of medicinal and pharmaceutical products will include various formulations with differing concentrations of cannabinoids suitable for diverse use-cases, allowing doctors to precisely prescribe according to a particular patient's age, weight and needs," commented Alejandro Antalich, Chief Executive Officer of ICC.